Efficacy and Safety of Treatment With Stapokibart in Adults With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
J Am Acad Dermatol 2024 Jul 20;[EPub Ahead of Print], Y Zhao, L Zhang, J ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.